Systolic Time Intervals a Prognostic Tool of Heart Failure in Emergency Departement (STI/AHF)
NCT ID: NCT03831204
Last Updated: 2020-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
642 participants
OBSERVATIONAL
2017-02-20
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Congestion and LActate at diScHarge in Acute Heart Failure
NCT07345156
Home Telemonitoring System for Patients With Heart Failure vs Usual Care
NCT04437849
Identification of Heart Failure Patients by Seismocardiography
NCT03656354
Therapeutic Education Strategy for Patients With Acute Heart Failure
NCT03035123
Prognostic Value of Delta LUS Score of Patients Hospitalized for Acute Heart Failure
NCT05871138
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
STI is an old technique based on the recording of two parameters: electrocardiogram and phonocardiogram, and from them measuring the different systolic intervals:
pre-ejection period (PEP),electro-mechanic activation time (EMAT), Left ventricular ejection time (LVET) and systolic time ratio (RTS) were measured.
The aim of these study is to demonstrate whether systolic time intervals (STIs) can improve clinical scores EFFECT (Enhanced Feedback for Effective Cardiac Treatment) and GWTG-HF (Get With the Guidelines-Heart Failure) for predicting 30 day mortality and readmission in patients with acute decompensated heart failure (ADHF) in the ED.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AHF/HFpEF
AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
biopac
Acoustic cardiography was performed for all participants using the BIOPAC system with "Student Lab" software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus.
prognostic scores
Effect and GWTGHF were calculated for every patient
AHF/HFrEF
AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
biopac
Acoustic cardiography was performed for all participants using the BIOPAC system with "Student Lab" software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus.
prognostic scores
Effect and GWTGHF were calculated for every patient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biopac
Acoustic cardiography was performed for all participants using the BIOPAC system with "Student Lab" software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus.
prognostic scores
Effect and GWTGHF were calculated for every patient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age more than 18 years old.
Exclusion Criteria
* ischemic chest pain within the prior 24 hours
* history of a heart transplant
* pericardial effusion
* chest wall deformity suspected of causing dyspnea
* coma
* shock,Mechanical Ventilation, vasopressor drugs
* arrhythmia serious and sustained,
* pace maker
* severe mitral valve disease,
* severe pulmonary arterial hypertension
* renal failure with creatinine \>350micromol/l
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Monastir
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr. Semir Nouira
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nouira Semir, Pr
Role: PRINCIPAL_INVESTIGATOR
University hospital of Monastir
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emergency department of university hospital Fattouma Bourguiba of Monastir Monastir, Monastir Tunisia
Monastir, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
official department website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STI in AHF prognostic
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.